Agenus Inc. (NASDAQ:AGEN) Given Average Rating of “Hold” by Brokerages

Agenus Inc. (NASDAQ:AGEN) has been given an average rating of “Hold” by the six analysts that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $10.00.

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a research report on Wednesday, January 22nd.

Institutional Investors Weigh In On Agenus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGEN. Corton Capital Inc. purchased a new stake in Agenus in the 4th quarter worth approximately $36,000. Virtu Financial LLC acquired a new position in shares of Agenus during the 4th quarter worth $51,000. Apollon Wealth Management LLC acquired a new position in shares of Agenus during the 4th quarter worth $55,000. EP Wealth Advisors LLC acquired a new position in shares of Agenus during the 3rd quarter worth $55,000. Finally, Bank of Montreal Can acquired a new position in shares of Agenus during the 4th quarter worth $69,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Stock Performance

Shares of NASDAQ:AGEN opened at $2.85 on Friday. The company has a market cap of $66.86 million, a PE ratio of -0.25 and a beta of 1.31. Agenus has a 52 week low of $2.50 and a 52 week high of $19.69. The firm has a 50 day simple moving average of $3.30 and a 200 day simple moving average of $4.01.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.